The global market for Phototherapy Treatment was valued at US$1.9 Billion in 2024 and is projected to reach US$2.4 Billion by 2030, growing at a CAGR of 3.4% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Phototherapy Treatment market.
In neonatal care, blue light phototherapy remains the gold standard for treating hyperbilirubinemia by converting unconjugated bilirubin into water-soluble isomers for easier excretion. This life-saving intervention has reduced the incidence of kernicterus and long-term neurological damage in newborns worldwide. With the increasing prevalence of skin conditions and rising awareness of the side effects associated with long-term steroid or systemic drug use, phototherapy is increasingly being preferred by both clinicians and patients seeking long-term, relapse-controlled management.
At-home phototherapy units, backed by physician oversight and app-based compliance monitoring, are gaining popularity among patients with chronic dermatologic conditions. These devices reduce the logistical burden of frequent clinic visits, while ensuring consistent dosing protocols. Wearable light patches and LEDs tuned to specific therapeutic wavelengths are being developed for low-dose, continuous treatment with minimal disruption to daily life. Advances in photodosimetry, AI-assisted treatment planning, and skin phototype analysis are enabling personalized regimens that improve outcomes and reduce phototoxicity risks.
North America and Europe lead in phototherapy infrastructure and dermatology specialization, with well-established treatment protocols and insurance coverage in many jurisdictions. Asia-Pacific is seeing rapid uptake due to high incidence of vitiligo and psoriasis, growing access to dermatological care, and expanding neonatal health initiatives. In emerging economies, mobile phototherapy units and NGO-supported equipment donations are improving access in rural clinics. Rising public health focus on skin disease burden is further driving awareness, early diagnosis, and treatment accessibility across diverse geographies.
Strategically, companies are investing in compact, AI-guided phototherapy systems with smart connectivity and adaptive dosage controls. Partnerships with dermatology clinics, hospitals, and maternal health networks are enabling large-scale deployment of both fixed and mobile units. Clinical trials investigating new wavelength combinations, photobiomodulation for wound healing, and dual-modality therapy (e.g., light + biologics) are expanding the therapeutic envelope of phototherapy. As regulatory frameworks evolve to support home-based medical technologies, phototherapy is poised to become a foundational tool in chronic disease management and personalized medicine.
Segments: Disease Type (Psoriasis Disease Type, Acne Disease Type); Phototherapy Type (Blue Light Phototherapy, Red Light Phototherapy, Intense Pulsed Light Phototherapy, Other Phototherapy Types); End-Use (Hospitals End-Use, Dermatology Clinics End-Use, Homecare Settings End-Use, Other End-Uses).
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
Global Phototherapy Treatment Market - Key Trends & Drivers Summarized
Why Is Phototherapy Becoming a Mainstay in the Treatment of Dermatological and Neonatal Conditions?
Phototherapy, the medical application of specific wavelengths of light to treat physiological or dermatological disorders, has become an essential modality in modern clinical practice. Widely used to manage chronic skin diseases such as psoriasis, vitiligo, eczema, and acne, as well as neonatal jaundice, phototherapy offers a non-invasive, drug-free option that modulates immune response, promotes cellular regeneration, and reduces inflammation. The controlled exposure to ultraviolet A (UVA), UVB, or narrowband UVB light can normalize skin cell growth and stimulate repigmentation, making it effective in both hospital and outpatient settings.In neonatal care, blue light phototherapy remains the gold standard for treating hyperbilirubinemia by converting unconjugated bilirubin into water-soluble isomers for easier excretion. This life-saving intervention has reduced the incidence of kernicterus and long-term neurological damage in newborns worldwide. With the increasing prevalence of skin conditions and rising awareness of the side effects associated with long-term steroid or systemic drug use, phototherapy is increasingly being preferred by both clinicians and patients seeking long-term, relapse-controlled management.
How Are Device Innovation and Treatment Personalization Enhancing Phototherapy Outcomes and Safety?
Technological advances in phototherapy devices have significantly improved treatment precision, safety, and patient adherence. Modern devices offer programmable UV dosage, skin-type calibration, real-time temperature monitoring, and targeted beam delivery, which minimizes overexposure and maximizes therapeutic impact. Narrowband UVB (NB-UVB) devices are now widely adopted for their ability to deliver effective treatment at lower carcinogenic risk compared to broadband UV systems. Handheld and comb devices allow for precision treatment in localized areas such as the scalp, hands, or feet.At-home phototherapy units, backed by physician oversight and app-based compliance monitoring, are gaining popularity among patients with chronic dermatologic conditions. These devices reduce the logistical burden of frequent clinic visits, while ensuring consistent dosing protocols. Wearable light patches and LEDs tuned to specific therapeutic wavelengths are being developed for low-dose, continuous treatment with minimal disruption to daily life. Advances in photodosimetry, AI-assisted treatment planning, and skin phototype analysis are enabling personalized regimens that improve outcomes and reduce phototoxicity risks.
Which Patient Populations and Therapeutic Areas Are Driving Phototherapy Adoption Globally?
Patients with autoimmune skin diseases - such as psoriasis, vitiligo, and atopic dermatitis - represent the largest beneficiary group for phototherapy, especially when systemic medications are contraindicated or have failed. Acne patients and those with cutaneous T-cell lymphoma or polymorphic light eruption also rely on phototherapy for sustained remission. In neonatal care, phototherapy remains integral to pediatric units, particularly in resource-constrained settings where alternative treatments are limited. Additionally, mental health research is exploring phototherapy for seasonal affective disorder (SAD) and circadian rhythm regulation.North America and Europe lead in phototherapy infrastructure and dermatology specialization, with well-established treatment protocols and insurance coverage in many jurisdictions. Asia-Pacific is seeing rapid uptake due to high incidence of vitiligo and psoriasis, growing access to dermatological care, and expanding neonatal health initiatives. In emerging economies, mobile phototherapy units and NGO-supported equipment donations are improving access in rural clinics. Rising public health focus on skin disease burden is further driving awareness, early diagnosis, and treatment accessibility across diverse geographies.
What Is Fueling Long-Term Growth and Strategic Innovation in the Phototherapy Market?
The growth in the phototherapy treatment market is driven by the rising incidence of dermatological conditions, a shift toward non-pharmacological therapies, and increasing awareness of skin health and neonatal care. With growing concerns around the long-term side effects of immunosuppressants and antibiotics, phototherapy is gaining ground as a safe, cost-effective, and repeatable treatment modality. The expansion of teledermatology and home-based care models is further accelerating patient adoption and treatment continuity.Strategically, companies are investing in compact, AI-guided phototherapy systems with smart connectivity and adaptive dosage controls. Partnerships with dermatology clinics, hospitals, and maternal health networks are enabling large-scale deployment of both fixed and mobile units. Clinical trials investigating new wavelength combinations, photobiomodulation for wound healing, and dual-modality therapy (e.g., light + biologics) are expanding the therapeutic envelope of phototherapy. As regulatory frameworks evolve to support home-based medical technologies, phototherapy is poised to become a foundational tool in chronic disease management and personalized medicine.
Report Scope
The report analyzes the Phototherapy Treatment market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments: Disease Type (Psoriasis Disease Type, Acne Disease Type); Phototherapy Type (Blue Light Phototherapy, Red Light Phototherapy, Intense Pulsed Light Phototherapy, Other Phototherapy Types); End-Use (Hospitals End-Use, Dermatology Clinics End-Use, Homecare Settings End-Use, Other End-Uses).
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Psoriasis Disease Treatment segment, which is expected to reach US$1.6 Billion by 2030 with a CAGR of a 2.8%. The Acne Disease Treatment segment is also set to grow at 4.6% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $528.3 Million in 2024, and China, forecasted to grow at an impressive 6.2% CAGR to reach $468.4 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Phototherapy Treatment Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Phototherapy Treatment Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Phototherapy Treatment Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Atom Medical Corporation, Daavlin, Dermalux, GE Healthcare, Herbert Waldmann GmbH & Co. KG and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 48 companies featured in this Phototherapy Treatment market report include:
- Atom Medical Corporation
- Daavlin
- Dermalux
- GE Healthcare
- Herbert Waldmann GmbH & Co. KG
- Hill-Rom
- Ibis Medical Equipment and Systems Pvt. Ltd.
- LumiThera
- Medela AG
- MTTS
- MuReva Phototherapy
- National Biological Corporation
- Natus Medical Incorporated
- NeoMedLight
- Nice Neotech Medical Systems Pvt. Ltd.
- Ningbo David Medical Device Co., Ltd.
- Phoenix Medical Systems Pvt. Ltd.
- Phothera
- Solarc Systems Inc.
- Tiny Hearts Technology
Tariff Impact Analysis: Key Insights for 2025
Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
What's Included in This Edition:
- Tariff-adjusted market forecasts by region and segment
- Analysis of cost and supply chain implications by sourcing and trade exposure
- Strategic insights into geographic shifts
Buyers receive a free July 2025 update with:
- Finalized tariff impacts and new trade agreement effects
- Updated projections reflecting global sourcing and cost shifts
- Expanded country-specific coverage across the industry
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPESOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Atom Medical Corporation
- Daavlin
- Dermalux
- GE Healthcare
- Herbert Waldmann GmbH & Co. KG
- Hill-Rom
- Ibis Medical Equipment and Systems Pvt. Ltd.
- LumiThera
- Medela AG
- MTTS
- MuReva Phototherapy
- National Biological Corporation
- Natus Medical Incorporated
- NeoMedLight
- Nice Neotech Medical Systems Pvt. Ltd.
- Ningbo David Medical Device Co., Ltd.
- Phoenix Medical Systems Pvt. Ltd.
- Phothera
- Solarc Systems Inc.
- Tiny Hearts Technology
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 384 |
| Published | May 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 1.9 Billion |
| Forecasted Market Value ( USD | $ 2.4 Billion |
| Compound Annual Growth Rate | 3.4% |
| Regions Covered | Global |
